{"id":"https://openalex.org/W2059623316","doi":"https://doi.org/10.1007/s13410-014-0191-1","title":"Saxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical study","display_name":"Saxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical study","alternate_titles":[],"publication_year":2014,"publication_date":"2014-01-31","ids":{"openalex":"https://openalex.org/W2059623316","doi":"https://doi.org/10.1007/s13410-014-0191-1","mag":"2059623316"},"language":"en","primary_location":{"id":"doi:10.1007/s13410-014-0191-1","doi":"https://doi.org/10.1007/s13410-014-0191-1","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s13410-014-0191-1","pdf_url":null,"source":{"id":"https://openalex.org/S201635232","display_name":"International Journal of Diabetes in Developing Countries","issn_l":"1998-3832","issn":["1998-3832","0973-3930"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","norway-1","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Diabetes in Developing Countries","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2059623316"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109573656","display_name":"K.M. PRASANNA KUMAR","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127127","display_name":"Bangalore Diabetes Centre","ror":"https://ror.org/033q83c72","country_code":"IN","type":"healthcare","lineage":["https://openalex.org/I4210127127"]}],"countries":["IN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K. M. Prasanna Kumar","raw_affiliation_strings":["Bangalore Diabetes Centre, Karnataka, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bangalore Diabetes Centre, Karnataka, India","institution_ids":["https://openalex.org/I4210127127"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sunil M. Jain","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142947","display_name":"TOTALL Diabetes Hormone Institute","ror":"https://ror.org/053sgn987","country_code":"IN","type":"healthcare","lineage":["https://openalex.org/I4210142947"]}],"countries":["IN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sunil M. Jain","raw_affiliation_strings":["TOTALL Diabetes Hormone Institute, Madhya Pradesh, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TOTALL Diabetes Hormone Institute, Madhya Pradesh, India","institution_ids":["https://openalex.org/I4210142947"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113489705","display_name":"Conrad Tou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Conrad Tou","raw_affiliation_strings":["Statistics and Programming Department, AstraZeneca LP, Wilmington, DE, USA","Statistics and Programming Department, AstraZeneca LP, Wilmington, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Statistics and Programming Department, AstraZeneca LP, Wilmington, DE, USA","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"Statistics and Programming Department, AstraZeneca LP, Wilmington, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112167379","display_name":"Kajs-Marie Sch\u00fctzer","orcid":"https://orcid.org/0000-0002-2611-2989","observed_orcids":["https://orcid.org/0000-0002-2611-2989"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Kajs-Marie Sch\u00fctzer","raw_affiliation_strings":["Global Medicines Development, AstraZeneca R&D, K\u00e4rragatan 5, M\u00f6lndal, Sweden, 43183","Global Medicines Development, AstraZeneca R&D, M\u00f6lndal, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medicines Development, AstraZeneca R&D, K\u00e4rragatan 5, M\u00f6lndal, Sweden, 43183","institution_ids":["https://openalex.org/I4210143795"]},{"raw_affiliation_string":"Global Medicines Development, AstraZeneca R&D, M\u00f6lndal, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5112167379"],"corresponding_institution_ids":["https://openalex.org/I4210143795"],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":1.8955,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":{"value":0.84521305,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":"34","issue":"4","first_page":"201","last_page":"209"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/saxagliptin","display_name":"saxagliptin","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.984000027179718},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.972000002861023},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.9300000071525574},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.8619999885559082},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.925000011920929},{"id":"https://openalex.org/keywords/indian-patients","display_name":"Indian patients","score":0.6809999942779541},{"id":"https://openalex.org/keywords/antihyperglycemic-therapy","display_name":"antihyperglycemic therapy","score":0.8529999852180481},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.8019999861717224},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6320000290870667}],"concepts":[{"id":"https://openalex.org/C2780282729","wikidata":"https://www.wikidata.org/wiki/Q3121121","display_name":"Saxagliptin","level":5,"score":0.9954487085342407},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9204286336898804},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7701843976974487},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6088323593139648},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.604618489742279},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5764970183372498},{"id":"https://openalex.org/C2778763485","wikidata":"https://www.wikidata.org/wiki/Q419770","display_name":"Dipeptidyl peptidase-4 inhibitor","level":4,"score":0.5586679577827454},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5440492033958435},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4533478915691376},{"id":"https://openalex.org/C2777538456","wikidata":"https://www.wikidata.org/wiki/Q311213","display_name":"Glycated hemoglobin","level":4,"score":0.4489438533782959},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.43847522139549255},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.43680691719055176},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.43078213930130005},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4237898588180542},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.22520524263381958},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.14701643586158752},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.05683225393295288},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1007/s13410-014-0191-1","doi":"https://doi.org/10.1007/s13410-014-0191-1","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s13410-014-0191-1","pdf_url":null,"source":{"id":"https://openalex.org/S201635232","display_name":"International Journal of Diabetes in Developing Countries","issn_l":"1998-3832","issn":["1998-3832","0973-3930"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","norway-1","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Diabetes in Developing Countries","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W131211302","https://openalex.org/W1532170875","https://openalex.org/W1605983684","https://openalex.org/W1970125713","https://openalex.org/W1991138829","https://openalex.org/W2009277908","https://openalex.org/W2020267609","https://openalex.org/W2039403622","https://openalex.org/W2045063167","https://openalex.org/W2048728983","https://openalex.org/W2095682936","https://openalex.org/W2103058881","https://openalex.org/W2109728760","https://openalex.org/W2111876001","https://openalex.org/W2114927834","https://openalex.org/W2126065052","https://openalex.org/W2146901298","https://openalex.org/W2166173635","https://openalex.org/W2172193326","https://openalex.org/W2772390855","https://openalex.org/W2789732774"],"related_works":["https://openalex.org/W2150483909","https://openalex.org/W2964545711","https://openalex.org/W1605983684","https://openalex.org/W1971471384","https://openalex.org/W2134884860","https://openalex.org/W1967861795","https://openalex.org/W7077142050","https://openalex.org/W2738308344","https://openalex.org/W4406464875","https://openalex.org/W2033331104"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2059623316","counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":4}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
